Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection

Li, Y; Hu, Y; Jin, Y; Zhang, G; Wong, J; Sun, LQ; Wang, M

Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection

Li, Y Hu, Y Jin, Y Zhang, G Wong, J Sun, LQ Wang, M

Permalink

Publication Type:: Journal Article
Citation:: Journal of Gene Medicine, 2011, 13 (1), pp. 60 - 72
Issue Date:: 2011-01-01

Closed Access

	Filename	Description	Size
	2010004790OK.pdf		918.83 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Li, Y	en_US
dc.contributor.author	Hu, Y	en_US
dc.contributor.author	Jin, Y	en_US
dc.contributor.author	Zhang, G	en_US
dc.contributor.author	Wong, J	en_US
dc.contributor.author	Sun, LQ	en_US
dc.contributor.author	Wang, M	en_US
dc.date.issued	2011-01-01	en_US
dc.identifier.citation	Journal of Gene Medicine, 2011, 13 (1), pp. 60 - 72	en_US
dc.identifier.issn	1099-498X	en_US
dc.identifier.uri	http://hdl.handle.net/10453/15604
dc.description.abstract	Background: In view of the magnitude and severity of outbreaks of the highly pathogenic H5N1 influenza virus (H5N1-HPIV) and the threat to public health, there is an urgent need to develop broad-spectrum prophylactic and therapeutic agents against infection by H5N1-HPIV and other subtypes. Methods and Results: In the present study, we explored the use of LE-PolyICLC, a liposome encapsulated double-stranded RNA, as a possible prophylactic, therapeutic and immune enhancement agent. In a mouse infection model, we showed that the administration of LE-PolyICLC intranasally before or shortly after infection could inhibit virus replication, leading to a significant reduction in pulmonary viral titres and a higher survival rate of infected mice. When used as a molecular adjuvant, LE-PolyICLC significantly enhanced both the humoral and cellular responses elicited by inactivated H5N1 vaccine and augmented the protective efficacy provided by vaccination. Most importantly, the data also demonstrate that LE-PolyICLC could effectively attenuate the development of pulmonary fibrosis during the restoration period at day 14 after H5N1 infection. +Conclusions: Taken together, the data obtained in the present study suggest that strong consideration should be given for the use of LE-PolyICLC as prophylactic and therapeutic agents and also as a vaccination adjuvant to combat highly pathogenic influenza infection and its associated complications such as pulmonary fibrosis. © 2011 John Wiley & Sons, Ltd.	en_US
dc.relation.ispartof	Journal of Gene Medicine	en_US
dc.relation.isbasedon	10.1002/jgm.1536	en_US
dc.subject.classification	Biotechnology	en_US
dc.subject.mesh	Lung	en_US
dc.subject.mesh	T-Lymphocytes	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Mice, Inbred BALB C	en_US
dc.subject.mesh	Dogs	en_US
dc.subject.mesh	Mice	en_US
dc.subject.mesh	Orthomyxoviridae Infections	en_US
dc.subject.mesh	Polylysine	en_US
dc.subject.mesh	RNA, Double-Stranded	en_US
dc.subject.mesh	RNA, Viral	en_US
dc.subject.mesh	Poly I-C	en_US
dc.subject.mesh	Vaccines, Inactivated	en_US
dc.subject.mesh	Influenza Vaccines	en_US
dc.subject.mesh	Adjuvants, Immunologic	en_US
dc.subject.mesh	Antibodies, Viral	en_US
dc.subject.mesh	Cytokines	en_US
dc.subject.mesh	Liposomes	en_US
dc.subject.mesh	Virus Replication	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Influenza A Virus, H5N1 Subtype	en_US
dc.subject.mesh	Carboxymethylcellulose Sodium	en_US
dc.title	Prophylactic, therapeutic and immune enhancement effect of liposome-encapsulated PolyICLC on highly pathogenic H5N1 influenza infection	en_US
dc.type	Journal Article
utslib.citation.volume	1	en_US
utslib.citation.volume	13	en_US
utslib.for	1103 Clinical Sciences	en_US
dc.location.activity	WOS:000287161100006	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
utslib.copyright.status	closed_access
pubs.issue	1	en_US
pubs.publication-status	Published	en_US
pubs.volume	13	en_US

Abstract:

Background: In view of the magnitude and severity of outbreaks of the highly pathogenic H5N1 influenza virus (H5N1-HPIV) and the threat to public health, there is an urgent need to develop broad-spectrum prophylactic and therapeutic agents against infection by H5N1-HPIV and other subtypes. Methods and Results: In the present study, we explored the use of LE-PolyICLC, a liposome encapsulated double-stranded RNA, as a possible prophylactic, therapeutic and immune enhancement agent. In a mouse infection model, we showed that the administration of LE-PolyICLC intranasally before or shortly after infection could inhibit virus replication, leading to a significant reduction in pulmonary viral titres and a higher survival rate of infected mice. When used as a molecular adjuvant, LE-PolyICLC significantly enhanced both the humoral and cellular responses elicited by inactivated H5N1 vaccine and augmented the protective efficacy provided by vaccination. Most importantly, the data also demonstrate that LE-PolyICLC could effectively attenuate the development of pulmonary fibrosis during the restoration period at day 14 after H5N1 infection. +Conclusions: Taken together, the data obtained in the present study suggest that strong consideration should be given for the use of LE-PolyICLC as prophylactic and therapeutic agents and also as a vaccination adjuvant to combat highly pathogenic influenza infection and its associated complications such as pulmonary fibrosis. © 2011 John Wiley & Sons, Ltd.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/15604